Mymetics Corp (MYMX)

[Work Harder]

Targeting Swine Influenza Virus with Sequivity Technology

https://www.merck-animal-health-usa.com/sequivity

Replication-deficient viruses

SEQUIVITY® product line (Merck; USA) can be customized to any virus

The last one has been licensed in the US as a vector for autogenous vaccine production (SEQUIVITY® product line; Merck, USA) and many such vaccines are now being used in the field.

There are several options for nanocarriers that can be used in nanovaccines including spores (bacterial), proteasomes (cell membrane based), exosomes (cellular), liposomes (lipid-based), virosomes (liposome and viral envelope protein), super fluids (biodegradable polymer), nanobeads (inert nanomaterial), VLPs (viral) and phages (viral, bacteria as targets)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780603/

So, since the end of April Mymetics / Baylor

Note the date here

May 27

* MERCK-BAYLOR TEAMS WILL IMPROVE MANUFACTURING PLATFORM FOR COV RBD219-N1 VACCINE CANDIDATE, WHICH WAS ORIGINALLY DEVELOPED TO TARGET SARS IN 2011-2016

* THEY WILL DEVELOP A NEW MANUFACTURING PLATFORM FOR A SECOND COVID-19 VACCINE CANDIDATE TO SHORTEN TIME TO ENTER INTO PHASE 1 CLINICAL TRIALS

* GOAL IS TO DEVELOP A SUITABLE MANUFACTURING PROCESS AND STEPS THAT WOULD LEAD TO A SCALE-UP APPROACH SUITABLE FOR PILOT AND LATER INDUSTRIAL PRODUCTION Source text for Eikon: Further company coverage:

https://www.reuters.com/article/brief-merck-kgaa-baylor-college-announce/brief-merck-kgaa-baylor-college-announce-covid-19-vaccine-collaboration-idUSFWN2D90K2

Better get um while they are still cheap, major exposure coming per Hugo himself

Ronald Kempers and the potential of a new COVID-19 nasal vaccine

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161249382

Come on COVAX give us some more Berlin Speed Desk